According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Other equities research analysts have also issued research reports about the stock. Roth Capital reaffirmed a buy rating and set a $17.00 target price on shares of Vascular Biogenics in a research note on Thursday, December 1st. Chardan Capital set a $20.00 price objective on shares of Vascular Biogenics and gave the stock a buy rating in a research note on Tuesday, November 29th. Finally, Piper Jaffray Companies reissued an overweight rating and set a $11.00 price objective on shares of Vascular Biogenics in a research note on Tuesday, February 21st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of $12.90.
Vascular Biogenics (NASDAQ:VBLT) traded up 4.81% during mid-day trading on Friday, reaching $5.45. The company had a trading volume of 238,718 shares. Vascular Biogenics has a 12-month low of $3.03 and a 12-month high of $7.58. The firm’s market capitalization is $146.62 million. The firm has a 50-day moving average price of $5.58 and a 200 day moving average price of $5.23.
Vascular Biogenics (NASDAQ:VBLT) last announced its earnings results on Monday, March 27th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. Analysts expect that Vascular Biogenics will post ($0.66) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Vascular Biogenics Ltd (VBLT) Downgraded to Sell at Zacks Investment Research” was originally posted by BBNS and is the property of of BBNS. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://baseballnewssource.com/markets/vascular-biogenics-ltd-vblt-lowered-to-sell-at-zacks-investment-research-updated-updated/525771.html.
A hedge fund recently bought a new stake in Vascular Biogenics stock. Knoll Capital Management LP bought a new stake in Vascular Biogenics Ltd (NASDAQ:VBLT) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 860,605 shares of the biopharmaceutical company’s stock, valued at approximately $4,406,000. Vascular Biogenics comprises approximately 7.7% of Knoll Capital Management LP’s holdings, making the stock its 4th largest position. Knoll Capital Management LP owned about 3.65% of Vascular Biogenics at the end of the most recent quarter. Institutional investors own 14.95% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vascular Biogenics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd and related companies with our FREE daily email newsletter.